Peppermint

This is peppermint's strongest evidence base by a wide margin, and it is worth walking through carefully - including the parts that do not flatter it.

The most useful summary is a 2022 systematic review and meta-analysis by Ingrosso and colleagues in Alimentary Pharmacology & Therapeutics. They searched the literature up to April 2022 and found 10 eligible randomised controlled trials covering 1,030 patients. Pooling them, peppermint oil beat placebo for global IBS symptoms (relative risk of not improving 0.65, number needed to treat 4) and for abdominal pain (relative risk of pain not improving 0.76, number needed to treat 7). A number needed to treat of 4 means roughly one extra person in four gets a benefit they would not have got from placebo - a respectable figure for a symptom-relief measure. An earlier 2019 meta-analysis by Alammar and colleagues in BMC Complementary and Alternative Medicine, covering 12 trials and 835 patients, reached a similar conclusion.

Now the honest problems. The Ingrosso authors themselves graded the quality of the pooled evidence as very low and wrote that adequately powered trials of peppermint oil as a first-line IBS treatment are still needed. Most of the individual trials are small, short (typically 4 to 12 weeks) and use different oil doses, different coatings and different symptom scales, which makes pooling them a rough exercise. And the single largest and most rigorous trial cuts the other way: Weerts and colleagues, published in Gastroenterology in 2020, randomised 189 Rome IV-diagnosed IBS patients across four Dutch hospitals to 182 mg small-intestinal-release peppermint oil, 182 mg ileocolonic-release peppermint oil, or placebo for eight weeks - and found no significant benefit for either formulation on the two primary endpoints, abdominal pain response and global symptom relief. A secondary measure of overall IBS severity did favour the small-intestinal-release version.

On the positive side of the individual trials, a 2016 study by Cash and colleagues in Digestive Diseases and Sciences randomised 72 people with diarrhoea-predominant or mixed IBS to a triple-coated sustained-release peppermint oil formulation (180 mg three times daily) or placebo for four weeks, and reported significantly greater reduction in total IBS symptom score, including abdominal pain and discomfort.

Where the professional bodies land: the American College of Gastroenterology's 2021 IBS guideline recommends peppermint oil for relief of global IBS symptoms - but as a conditional recommendation based on low-quality evidence, specifically in enteric-coated capsule form rather than liquid, for short-term use. That phrasing is doing a lot of careful work, and it is a fair summary of the field.

One more thing that never makes the headlines: side effects were significantly more common with peppermint oil than placebo in the Ingrosso analysis, and the commonest ones were reflux and indigestion - caused by the same muscle-relaxing action that makes the oil useful lower down. Enteric coating exists largely to reduce that.

The honest read: for adults with diagnosed IBS, enteric-coated peppermint oil is one of the better-supported non-prescription options, with a modest effect size, a short evidence window and real quality caveats. None of that carries over to peppermint tea or to leaf extract powder.

Functional dyspepsia is the clinical term for persistent indigestion - upper-abdominal pain or burning, uncomfortable fullness after meals, early satiety - with no ulcer or other structural cause to explain it. Peppermint has been studied here, but almost always as half of a two-oil combination.

The product in question is Menthacarin, a proprietary preparation of 90 mg peppermint oil plus 50 mg caraway oil per capsule. A 2017 randomised, double-blind, placebo-controlled multicentre trial by Rich and colleagues, published in Neurogastroenterology & Motility, enrolled 114 outpatients with chronic or recurrent functional dyspepsia and gave them either Menthacarin (one capsule twice daily) or placebo for four weeks. The combination improved pain and discomfort and disease-specific quality of life relative to placebo, across both of the recognised dyspepsia sub-patterns - epigastric pain syndrome and postprandial distress syndrome. A 2023 systematic review and meta-analysis by Madisch and colleagues in Digestive Diseases pulled together five randomised trials covering 580 patients and found significant effects on functional dyspepsia symptoms versus placebo, or comparable effects versus an active reference drug.

The limitations are straightforward and important. Five trials in 580 people is a modest body of work. Nearly all of it centres on one commercial product from one manufacturer, which is not the same as an independent evidence base. And crucially, you cannot tell from these trials how much of the effect belongs to peppermint and how much to caraway - the two were never separated. NCCIH puts the conclusion bluntly: specific combination products containing peppermint oil plus caraway oil may help relieve indigestion, but there is no evidence that peppermint oil alone does, and peppermint oil taken alone may actually worsen indigestion in some people.

That last point deserves a beat. Indigestion and reflux are neighbours, and peppermint's muscle-relaxing effect on the oesophageal valve can tip one into the other. Some people find peppermint settles a heavy stomach; some find it does the opposite. There is no reliable way to predict which you are except to try gently and pay attention.

Separately from all of the above, Health Canada does permit peppermint - leaf or essential oil - to carry the traditional wording of a carminative used to help relieve flatulent dyspepsia. That is a traditional-use permission grounded in centuries of herbal practice, not a modern clinical finding, and the two should not be confused.

This is the oldest and least glamorous entry on the list, and also the one that actually applies to peppermint leaf - the form in tea and in our 10:1 extract.

Health Canada's peppermint monograph permits two digestive statements for all peppermint products, leaf included: traditionally used in Herbal Medicine as a stomachic to aid digestion, and traditionally used in Herbal Medicine as a carminative to help relieve flatulent dyspepsia. In plain English: a herb taken to help the stomach do its job, and a herb taken to help with wind and the bloated, gassy pressure that comes with it. The monograph is explicit that these are traditional-use claims, drawn from the herbal literature - Commission E, ESCOP, the British Herbal Compendium, King's American Dispensatory - rather than from modern clinical trials.

The permitted doses for adults run from 1.2 g up to 12 g of dried leaf per day, with lower ceilings for children and adolescents. That is a wide window, and the upper end is a lot of peppermint - well beyond what most people would take.

What the leaf does not have is a clinical file. NCCIH states directly that very little research has been done on peppermint leaf and that there is not enough evidence to determine whether it is useful for any health condition. The most-cited overview of the tea, a 2006 review by McKay and Blumberg in Phytotherapy Research, catalogued the leaf's polyphenols - rosmarinic acid, eriocitrin, luteolin, hesperidin - and summarised antimicrobial, antioxidant and gut-relaxing findings, but those results came from test tubes and animal models, not from randomised trials in people.

So the honest framing is this: peppermint leaf is a traditional digestive herb with a very long, very consistent history of use, formal regulatory recognition of that tradition in Canada, an excellent safety record at normal amounts, and essentially no modern human efficacy data of its own. That is not nothing - traditional use is a real category, and Health Canada treats it as one - but it is a different and lower tier of evidence than the oil-in-IBS work, and anyone selling you leaf on the strength of oil studies is misleading you.

Health Canada's monograph is precise here in a way that is easy to miss. The statement traditionally used in Herbal Medicine to help relieve nausea and vomiting is granted to peppermint essential oil only. Peppermint dried leaf does not carry it. If you are drinking peppermint tea for queasiness you are in the realm of long custom rather than permitted claim wording, and that is worth being clear about.

On the modern research, most of what exists comes from cancer care. A 2024 systematic review and meta-analysis by Ahn and colleagues in Complementary Therapies in Clinical Practice examined aromatherapy for nausea and vomiting in cancer patients; it covered 10 studies overall, of which 4 studies involving 290 participants used peppermint oil, and found inhaled peppermint oil particularly effective at reducing nausea and vomiting in people undergoing chemotherapy. NCCIH summarises the wider picture as a small amount of research suggesting that taking peppermint extract by mouth or inhaling peppermint oil can help reduce chemotherapy-related nausea and vomiting.

The caveats are the usual ones for this kind of research, and they are not trivial. Aromatherapy trials are very hard to blind - a participant knows immediately whether the thing under their nose smells of peppermint - so expectation effects are difficult to rule out. The individual studies are small. The setting is specific: chemotherapy-induced nausea in a hospital, which is not the same problem as travel sickness, a hangover, morning sickness or a rough stomach after a bad meal. And peppermint's effect on the oesophageal valve means that in some people it can make an upset stomach feel worse rather than better.

The honest read: there is a genuine, if modest and hard-to-blind, signal for inhaled peppermint oil in one well-defined clinical situation, plus a formally recognised traditional use for the essential oil taken orally. Extending either to peppermint tea, or to nausea in general, goes further than the evidence does. And nausea that is persistent, severe or unexplained is a reason to see a doctor, not to reach for a herb.

The single study everyone cites is a 1996 German trial by Gobel and colleagues, published in Nervenarzt, and it is genuinely well designed for its era. Forty-one adults aged 18 to 65 with tension-type headache each treated four separate headache attacks - 164 attacks in total - in a randomised, double-blind, placebo-controlled crossover design. Each attack was treated with both an oral tablet (1,000 mg acetaminophen or a dummy) and a skin application (a solution of 10% peppermint oil in 90% ethanol, or a placebo ethanol solution with a trace of peppermint added so it smelled the same). The preparation was spread across the forehead and temples and reapplied at 15 and 30 minutes.

The result: compared with placebo application, the 10% peppermint oil solution significantly reduced headache intensity from 15 minutes onward, and the reduction held across the one-hour observation period. Acetaminophen also beat placebo. The design is the strength here - crossover means each person acted as their own control, and the scented placebo was a real attempt to solve the obvious blinding problem with a strongly aromatic treatment.

Why this is still graded preliminary thirty years on: it is essentially one study in 41 people, published in German in 1996, and it has not been convincingly replicated at scale in the decades since. NCCIH's summary is that a limited amount of evidence suggests topically applied peppermint oil might relieve tension headaches - the hedging is deliberate. And even a well-scented placebo cannot fully hide the intense cooling sensation of menthol on skin, which is a plausible route for expectation to influence a subjective pain score.

Practical notes if you try it. This means a properly diluted essential oil applied to the temples and forehead - never neat oil, never near the eyes, and never on the face of a child, where inhaled menthol is a genuine breathing hazard. Peppermint oil on skin can cause rashes and irritation, so patch-test first. And none of this has any bearing on drinking peppermint tea or taking a leaf extract, which is a completely different route into the body. Migraine is also a different condition from tension headache, and this trial says nothing about it.